A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

Name: A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)
Published: 2023
License: Public Domain

AstraZeneca · 2023

ClinicalTrials.gov · Datasets · License: Public Domain · 2023

Open Source ↗

stage ii-iiib non-small cell lung carcinoma, stage ii-iiib non-small cell lung cancer, adjuvant osimertinib, adjuvant chemotherapy, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

Related documents